In a cohort of 53 pediatric patients aged 11 months to 17 years with AML (52 with de novo AML, 1 with secondary AML), no recurrent SF3B1 mutations were identified, suggesting that SF3B1 mutations are unlikely to be a leukemogenic driver in childhood AML [52]. Here, SF3B1 is linked to acute myeloid leukemia.